dr. krumholz wants and i want to.ally do need the outcome trials, but it's about balancing what's in the public interest. i agree with the fda. i think it's in the public interest to get the drugs to market now for the people that are most in need. >> dr. krumholz, how much are some of the drugs going to cost? is it the standard where the first ones cost a lot and once you make a billion of them they get cheaper? >> i think it's hard for me to determine on what basis we're pricing drugs. if you look at any of the cancer drugs, the hep c drugs, they're coming out at extraordinarily high cost and it's hard to know exactly where this will be priced. i think it's impossible to know about the value the drugs are bringing until we have the other studies completed and know what effect the drugs have on people's lives. so i'm in agreement with dr. nissen. i think it's important to give early access if possible to people who have little choice or for whom cholesterol represents their biggest risk and for whom they're not reall